Gram-Negative Bacteria Stocks

Biopharmaceutical firms in this sector develop targeted anti-infectives and vaccines to combat multidrug-resistant pathogens characterized by a dual-membrane structure that inherently resists many traditional antibiotics.

As of Oct 23, 2026, Gram-Negative Bacteria has 4 US-listed companies worth $1.1B combined. The median member moved +8.1% over the past week; INDP led at +20.2% and SPRO trailed at +0.9%.